Unmet needs in the prediction and detection of metastases in prostate cancer.
暂无分享,去创建一个
Oliver Sartor | Michael W Kattan | M. Kattan | B. Tombal | F. Lecouvet | O. Sartor | M. Eisenberger | Mario Eisenberger | Frederic Lecouvet | Bertrand Tombal
[1] M. Gleave,et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. , 2012, The Journal of urology.
[2] S. Freedland,et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. , 2004, The Journal of urology.
[3] F. Keeley,et al. Laparoscopic lymph node sampling in locally advanced prostate cancer. , 2002, BJU international.
[4] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[5] J. Moul,et al. Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer* , 2005, Current opinion in urology.
[6] O. Schober,et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.
[7] S. Hazell,et al. Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression , 2011, Clinical Cancer Research.
[8] Laurence Collette,et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.
[9] B. Tombal,et al. Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? , 2011, Advances in urology.
[10] E. Antonarakis,et al. Changes in PSA kinetics predict metastasis‐free survival in men with PSA‐recurrent prostate cancer treated with nonhormonal agents , 2012, Cancer.
[11] H. Scher,et al. Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy , 2005, Clinical Cancer Research.
[12] Pierre I Karakiewicz,et al. An updated catalog of prostate cancer predictive tools , 2008, Cancer.
[13] C. Claussen,et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer , 2006, Nuklearmedizin.
[14] J Kotzerke,et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer , 2003, Nuklearmedizin.
[15] L. Rybak,et al. Radiological imaging for the diagnosis of bone metastases. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[16] P. Therasse,et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Thomas Wiegel,et al. Guidelines on Prostate Cancer , 2013 .
[18] N. Spry,et al. 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[19] Maria Triantafyllou,et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. , 2009, European urology.
[20] S. Larson,et al. 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo , 2010, The Journal of Nuclear Medicine.
[21] Y. Erdi,et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] H. Thaler,et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? , 1996, The Journal of urology.
[23] T. Au-yong,et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain , 1998, European Journal of Nuclear Medicine.
[24] Stone Nn,et al. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer , 1999 .
[25] F. Saad,et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R Weissleder,et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. , 1999, AJR. American journal of roentgenology.
[27] C. Dence,et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[28] Heiko Schöder,et al. Positron emission tomography for prostate, bladder, and renal cancer. , 2004, Seminars in nuclear medicine.
[29] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[30] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[31] P. Waldenberger,et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[32] R. Weissleder,et al. Detection of lymph node metastases by contrast‐enhanced MRI in an experimental model , 2002, Magnetic resonance in medicine.
[33] H. Schirrmeister,et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] B. Trock,et al. The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up , 2012, BJU international.
[35] P. Kantoff,et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] U. Metser,et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] S. Boorjian,et al. Dynamic prediction of metastases after radical prostatectomy for prostate cancer , 2011, BJU international.
[38] N. Sanfilippo,et al. Management of High-Risk Localized Prostate Cancer , 2011, Advances in urology.
[39] E. Melhem,et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. , 1997, AJR. American journal of roentgenology.
[40] J. Moul,et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. , 2003, Urology.
[41] M. Kattan,et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] N F Wasserman,et al. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. , 1992, Urology.
[43] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[44] D. Mankoff,et al. C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases: Relative Findings and Response to Therapy , 2011, Clinical nuclear medicine.
[45] J. Mohler,et al. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. , 1991, The Journal of urology.
[46] J. Moul,et al. Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer* , 2005, Current opinion in urology.
[47] F. Saad,et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.
[48] F. Saad,et al. A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] T. Nozaki,et al. Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer , 2008, International journal of urology : official journal of the Japanese Urological Association.
[50] J. Pruim,et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] R. Eeles,et al. Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer , 2009, Journal of medical imaging and radiation oncology.
[52] Y. Erdi,et al. Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .
[53] M. Picchio,et al. The role of PET/computed tomography scan in the management of prostate cancer , 2011, Current opinion in urology.
[54] M. Kattan,et al. Comparisons of nomograms and urologists' predictions in prostate cancer. , 2002, Seminars in urologic oncology.
[55] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[56] E. Antonarakis,et al. The effect of PSA doubling time (PSADT) and Gleason score on the PSA at the time of initial metastasis in men with biochemical recurrence after prostatectomy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] E. Antonarakis,et al. Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database , 2011, BJU international.
[58] B. Trock,et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. , 2008, The Journal of urology.
[59] Y. Kuo,et al. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. , 2011, Urologic oncology.
[60] H. Scher,et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] G. Andriole,et al. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.
[62] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.
[63] Naoto T Ueno,et al. Bone imaging in metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Josef Hammer,et al. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT , 2010, Molecular Imaging and Biology.
[65] Yun Yen,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[66] J. Carles,et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). , 2012 .
[67] G. Cook,et al. MRI or bone scan or both for staging of prostate cancer? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] B. Tombal,et al. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa) , 2010, European Radiology.
[69] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[70] J. Nelson,et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer , 2011, Cancer.
[71] Kazutaka Saito,et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. , 2008, European urology.
[72] A. Partin,et al. The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. , 2006, Reviews in urology.
[73] P. Walsh,et al. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. , 2010, The Journal of urology.
[74] M. Poupon,et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] F. Saad,et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer , 2008, Cancer.
[76] Ralph Weissleder,et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.
[77] A. Haese*,et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. , 2006, The Journal of urology.
[78] M. Langer,et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. , 2005, European journal of radiology.
[79] V. Vigorita,et al. Localization of technetium‐99m methylene diphosphonate in bone using microautoradiography , 1986, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.